Trial Profile

A Multicenter, Randomized Phase II/III Clinical Study to Evaluate the Efficacy and Safety of GenaKumab in the Treatment of Active Systemic Juvenile Idiopathic Arthritis

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 22 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Firsekibart (Primary) ; Tocilizumab
Indications Juvenile rheumatoid arthritis
Focus Therapeutic Use
Sponsors GeneScience Pharmaceuticals

Most Recent Events

17 Sep 2026 Planned number of patients changed from 221 to 290.
07 May 2026 According to GeneScience Pharmaceuticals media release, data from the trial were presented in Rheumatology and Therapy.
23 Sep 2024 Planned number of patients changed from 30 to 221.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com